--- 
#Jekyll front matter 
layout: default 
title: CAR-T Cell Immunotherapy 
description: 
parent: sequence-two 
---
<div class="pageHeading">
    <h1>Cancer (target cells)</h1>
</div>
<div class="content">
    <ul class="tabs clearfix">
        <li><a href="{{ site.baseurl }}/sequence-two/index.html">Module 1</a></li>
        <li><a href="{{ site.baseurl }}/sequence-two/module2.html">Module 2</a></li>
        <li><a href="{{ site.baseurl }}/sequence-two/module3.html" class="current">Module 3</a></li>
    </ul>
    <h2>Ethics of cancer treatment</h2>
    <p class="intro">The THIRD module within SEQUENCE 2 focuses on identifying the ethical issues around the design and testing of contemporary cancer treatments.  It is possible that this module could take 3 hours of class time.</p>
    <h3>Summary</h3>
    <div class="col-2max module-info">
        <div>
            <h4>VCE Key Knowledge Biology Study Design (2017-2021)</h4>
            <p>Unit 4: How does life change and respond to challenges over time? Area of Study 2: How do humans impact on biological processes? (<a class="new-tab-warning" href="http://www.vcaa.vic.edu.au/Documents/vce/biology/BiologySD-2016.pdf" target="_blank">VCE Biology Study Design</a>)</p>
            <p>Key knowledge:</p>
            <ul>
                <li>Analyse the interrelationship between scientific knowledge and its application in society</li>
                <li>Social and ethical implications and issues surrounding CAR T-cell cancer treatments</li>
            </ul>
        </div>
        <div>
            <h4>Duration</h4>
            <p><img src="{{ site.baseurl }}/img/time.svg" alt="" class="clock"> 3 hours</p>
            <h4>Student learning outcomes</h4>
            <p>On completion of this module, students will:</p>
            <ul>
                <li>Identify the ethical issues around cancer drug design and delivery</li>
            </ul>
        </div>
    </div>
    <h3>Teacher background information</h3>
    <h4>Additional introductory resources</h4>
    <div class="resources col-3max flex">
        <div class="resource web">
            <div>
                <h5>Article</h5>
                <p><strong>Frameworks for Ethical analysis</strong></p>
                <div class="description">
                   
                </div>
                <a class="open" href="http://biotechlearn.org.nz/themes/bioethics/frameworks_for_ethical_analysis">Open</a>
            </div>
            <div class="overlay">
                <a class="open-new-tab" href="http://biotechlearn.org.nz/themes/bioethics/frameworks_for_ethical_analysis" target="_blank">Open in new tab</a>
            </div>
        </div>
        <div class="resource web">
            <div>
                <h5>Article</h5>
                <p><strong>Ethical dilemmas in fighting infection</strong></p>
                <div class="description">
                    <p>Note: this process is for some of the stories that the particular web site has focused on. The same process/concept could be used for the discussion of social and ethical implications around T cell therapy and other immunotherapies. Issues such as:</p>
                    <ul>
                        <li>Unknown side effects</li>
                        <li>Access to clinical trials</li>
                    </ul>
                </div>
                <a class="open" href="http://sciencelearn.org.nz/Contexts/Fighting-Infection/Teaching-and-Learning-Approaches/Ethical-dilemmas-in-fighting-infection">Open</a>
            </div>
            <div class="overlay">
                <a class="open-new-tab" href="http://sciencelearn.org.nz/Contexts/Fighting-Infection/Teaching-and-Learning-Approaches/Ethical-dilemmas-in-fighting-infection" target="_blank">Open in new tab</a>
            </div>
        </div>
    </div>
    <p>Thought: Fast-tracking therapies based on a small (but high percentage) of success rates.</p>  
    <p>Question:  CAR T-cell therapy is used for patients with end-stage cancer where other available treatments have failed.  If CAT T therapy successfully ensures remission in a number of patients, why do we need so many clinical trials? Why canâ€™t the treatment be available to everyone?</p>
    <div class="resources col-3max flex">
        <div class="resource web">
            <div>
                <h5>Resource</h5>
                <p><strong>TES: Monoclonal Antibodies lesson</strong></p>
                <div class="description">
                   <p>Asks students to investigate the ethics of the use of animals in creating monoclonal 	antibodies, and the risks to humans in clinical trials of cancer treatments. Includes worksheets, presentation and a range of questions pertaining to ethics.</p>
                </div>
                <a class="open" href="https://www.tes.com/teaching-resource/monoclonal-antibodies-lesson-6426297">Open</a>
            </div>
            <div class="overlay">
                <a class="open-new-tab" href="https://www.tes.com/teaching-resource/monoclonal-antibodies-lesson-6426297" target="_blank">Open in new tab</a>
            </div>
        </div>
        <div class="resource web">
            <div>
                <h5>Resource</h5>
                <p><strong>TES Australia: Herceptin the story of a new medicine</strong></p>
                <div class="description">
                    <p>A powerpoint presentation that provides an outline on how the monoclonal antibody Herceptin is developed using animals. Can be used as a case study to discuss the ethics of cancer research.</p>
                </div>
                <a class="open" href="https://www.tes.com/teaching-resource/herceptin-the-story-of-a-new-medicine-6398942">Open</a>
            </div>
            <div class="overlay">
                <a class="open-new-tab" href="https://www.tes.com/teaching-resource/herceptin-the-story-of-a-new-medicine-6398942" target="_blank">Open in new tab</a>
            </div>
        </div>
    </div>
</div>